Resverlogix Supports Epigenetics Satellite Symposium and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
53
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich

Key Opinion Leaders gather to discuss: LDL-c: Done Deal, Next Epigenetics? Dr. Ewelina Kulikowski of Resverlogix to present data on the effect of apabetalone on vascular inflammation

CALGARY, Alberta, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX ) today announced it is supporting a satellite symposium on August 25 th , 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics?

Satellite Symposium Agenda

15:30 - 15:35 (local time): Introduction Ulrich Laufs, MD – Leipzig, Germany

15:35 - 15:50: The real residual risk in patients with CVD & diabetes: The promise of epigenetics Erik Stroes, MD – Amsterdam, Netherlands

15:50 - 16:10: Understanding epigenetics: The potential rationale for BET inhibition in management of CVD Jorge Plutzky, MD – Boston, USA

16:10 - 16:25: A clinical view on BET inhibition in targeting residual risk in CVD and diabetes Kausik Ray, MD

16:25 – 16:30: Discussion & summary Co-Chairmen Kausik Ray, MD Ulrich Laufs, MD

Symposium presentations and videos will be posted to the Company website HERE once available.

Satellite Symposium Educational Objectives

  • To summarize the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
  • To understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
  • To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
  • To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

In addition to the satellite symposium, Dr. Ewelina Kulikowski, Senior Vice President of Research & Development of Resverlogix will provide an oral presentation during the Basic and Translational Science Hot Line - Vascular Biology session on Aug. 27, 2018 at 15:00 (local time), titled: Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta.

In Other News

Resverlogix will be participating at the following upcoming conferences:

  • 20 th Annual Rodman & Renshaw Global Investment Conference, September 4-6, 2018, New York City
  • NewsMakers in the Biotech Industry, September 7 th , 2018, New York City
  • BIO Investor Forum, October 17-18, 2018, San Francisco

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX ).

Follow us on Twitter: @Resverlogix_RVX

For further information please contact:

Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, Alzheimer's disease, Fabry disease, and Orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 92

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 31

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 90

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 162

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
SAP Execution Can Steady Operations Beyond Spreadsheets

Updated Category News Views 87

Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Huawei's Financial AI Push Targets Scale, Not Demos

Updated Category News Views 23

Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 44

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Autohome Inc.'s Financial Results for 2025

Updated Category News Views 150

Autohome Inc.'s Upcoming Financial Results Announcement Autohome Inc. (NYSE: ATHM) is on the verge of announcing its financial results for the second quarter and six months period ending June 30, 2025. As a leading platform for automobile consumers, Autohome continues to grow and adapt in an evolving market. Key Details on the Earnings Announcement The earnings report...

Continue Reading
NEXGEL Welcomes Industry Expert Kip Crecca to Advisory Team

Updated Category News Views 100

NEXGEL Expands Scientific Expertise with New Appointment NEXGEL, Inc. (NASDAQ: NXGL), renowned for its innovative medical and over-the-counter (OTC) products, has recently announced an exciting development. The company is thrilled to welcome Kip Crecca to its Scientific Advisory Board. This strategic addition showcases NEXGEL's dedication to enhancing its healthcare...

Continue Reading
Exciting Mixed-Use Development Takes Shape in Downtown Area

Updated Category News Views 318

Reimagining Urban Spaces: The Lewter District Development In an exciting development for urban living, RNGD and Emergent Properties are pioneering a remarkable mixed-use community known as the Lewter District. This project is set on a 1.5-acre plot, featuring 14 townhomes, a Class A office building, and an inviting farm-to-table restaurant, bar, and bakery. It's an...

Continue Reading
37th Parallel Expands DFW Footprint with Key Acquisition

Updated Category News Views 97

Picking Up Momentum in Dallas-Fort Worth Real Estate 37th Parallel Properties isn't messing around in the Dallas-Fort Worth market. They've snapped up Woodbridge Villas, a prime multifamily asset with 222 units tucked away in Sachse, Texas—a place with more charm than lawn gnomes in spring. This acquisition helps them expand their already hefty footprint in the South...

Continue Reading
Microchip Technology Announces Revenue Changes and Restructuring

Updated Category News Views 169

Microchip Technology's Updated Revenue Guidance for December Quarter Recently, Microchip Technology Incorporated, a prominent provider of smart embedded control solutions, has updated its revenue outlook for the upcoming quarter. The latest forecasts indicate a decline, with expectations set close to the lower end of their original guidance at $1.025 billion. This...

Continue Reading